Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e01556-19. doi: 10.1128/AAC.01556-19. Print 2019 Nov.

PMID:
31481440
2.

Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01572-18. doi: 10.1128/AAC.01572-18. Print 2018 Nov.

3.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02154-17. doi: 10.1128/AAC.02154-17. Print 2018 Feb.

4.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, Bhavnani SM, Ambrose PG.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02614-17. doi: 10.1128/AAC.02614-17. Print 2018 Jun.

5.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.

6.

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.

Miesel L, Lin KY, Ong V.

Pharmacol Res Perspect. 2019 Nov 20;7(6):e00546. doi: 10.1002/prp2.546. eCollection 2019 Dec.

7.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

8.

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J.

Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. Epub 2007 Dec 10.

9.

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Locke JB, Almaguer AL, Donatelli JL, Bartizal KF.

Infect Dis Obstet Gynecol. 2018 Feb 22;2018:7040498. doi: 10.1155/2018/7040498. eCollection 2018.

10.

In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J.

Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.

11.

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.

Arendrup MC, Meletiadis J, Zaragoza O, Jørgensen KM, Marcos-Zambrano LJ, Kanioura L, Cuenca-Estrella M, Mouton JW, Guinea J.

Clin Microbiol Infect. 2018 Nov;24(11):1200-1204. doi: 10.1016/j.cmi.2018.02.021. Epub 2018 Mar 2.

12.

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.

Hager CL, Larkin EL, Long LA, Ghannoum MA.

J Antimicrob Chemother. 2018 Aug 1;73(8):2085-2088. doi: 10.1093/jac/dky153.

13.

In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.

Hall D, Bonifas R, Stapert L, Thwaites M, Shinabarger DL, Pillar CM.

Diagn Microbiol Infect Dis. 2017 Nov;89(3):205-211. doi: 10.1016/j.diagmicrobio.2017.07.007. Epub 2017 Jul 21.

PMID:
28826987
14.

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jan;48(1):137-42.

15.

Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Lepak AJ, Marchillo K, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. doi: 10.1128/AAC.04445-14. Epub 2014 Dec 15.

16.

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Andes D, Marchillo K, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Oct;47(10):3165-9.

17.

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506. doi: 10.1128/AAC.01584-09. Epub 2010 Apr 12.

18.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

19.

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

Andes D, Marchillo K, Stamstad T, Conklin R.

Antimicrob Agents Chemother. 2003 Apr;47(4):1193-9.

20.

In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.

Boikov DA, Locke JB, James KD, Bartizal K, Sobel JD.

J Antimicrob Chemother. 2017 May 1;72(5):1355-1358. doi: 10.1093/jac/dkx008.

Supplemental Content

Support Center